Sonoma Pharmaceuticals announces 1-for-20 reverse stock split effective Aug 29 to maintain Nasdaq listing

Sonoma Pharmaceuticals, Inc.

Authorized shares increased from 24M to 50M; reverse split ratio 1:20 effective Aug 29, 2024 at 5pm EDT.
Post-split common shares outstanding ~1M; trading begins on split-adjusted basis Aug 30, 2024.
Split intended to meet Nasdaq $1 minimum bid price requirement by Sept 16, 2024; no assurance of compliance.
Stockholders re-elected Philippe Weigerstorfer and Amy Trombly as Class I directors; reincorporation to Nevada not approved.
All proposals at annual meeting approved except reincorporation; auditor ratified.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.